Apellis (APLS) Pharmaceuticals announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Walbert most recently served as executive vice president, U.S. commercial, at Horizon Therapeutics. Walbert’s appointment expands the Board to seven directors, six of whom are independent.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target raised to $26 from $24 at RBC Capital
- Unity Biotechnology appoints Grossi as Chief Medical Officer
- Apellis downgraded to Neutral from Buy at Goldman Sachs
- Biotech Alert: Searches spiking for these stocks today
- Ulta Beauty downgraded, Palo Alto upgraded: Wall Street’s top analyst calls